-
1Academic Journal
Authors: Korolyova A.A., Gerasimov S.S., Lyubchenko L.N.
Contributors: The study was conducted without sponsorship, Исследование проведено без спонсорской поддержки
Source: Advances in Molecular Oncology; Vol 11, No 1 (2024); 105-112 ; Успехи молекулярной онкологии; Vol 11, No 1 (2024); 105-112 ; 2413-3787 ; 2313-805X
Subject Terms: factor V Leiden, prothrombin G(20210)A mutation, malignant thoracoabdominal tumors, myocardial infarction, ischemic stroke, venous thromboembolism, мутация Лейдена, мутация протромбина G(20210)A, злокачественные опухоли торакоабдоминальной локализации, инфаркт миокарда, ишемический инсульт, венозный тромбоэмболизм
File Description: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/653/342; https://umo.abvpress.ru/jour/article/view/653
-
2Academic Journal
Authors: Cherniy, V.I., Smirnova, N.N., Egorov, A.A., Kolganova, E.A., Bosko, I.L.
Source: МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; Том 16, № 5 (2020); 45-49
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; Том 16, № 5 (2020); 45-49
EMERGENCY MEDICINE; Том 16, № 5 (2020); 45-49Subject Terms: венозний тромбоемболізм, онкологічні хворі, профілактика, низькомолекулярний гепарин, 03 medical and health sciences, 0302 clinical medicine, 3. Good health, венозный тромбоэмболизм, онкологические больные, профилактика, низкомолекулярный гепарин, venous thromboembolism, cancer patients, prevention, low molecular weight heparin
File Description: application/pdf
-
3Academic Journal
Authors: Yu. A. Vasyuk, E. Y. Shupenina, A. G. Nosova, E. O. Novosel, D. A. Vyzhigin, Ю. А. Васюк, Е. Ю. Шупенина, А. Г. Носова, Е. О. Новосел, Д. А. Выжигин
Source: Rational Pharmacotherapy in Cardiology; Vol 19, No 2 (2023); 203-208 ; Рациональная Фармакотерапия в Кардиологии; Vol 19, No 2 (2023); 203-208 ; 2225-3653 ; 1819-6446
Subject Terms: фактор роста эндотелия сосудов, vasotoxicity, endothelial dysfunction, venous thromboembolism, arterial thrombosis, chemotherapy, alkylating agent, antimetabolites, tyrosine kinase inhibitors, vascular endothelial growth factor, вазотоксичность, эндотелиальная дисфункция, венозный тромбоэмболизм, артериальный тромбоз, химиотерапи, алкилирующие агенты, антиметаболиты, ингибиторы тирозинкиназы
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2841/2418; https://www.rpcardio.com/jour/article/downloadSuppFile/2841/781; https://www.rpcardio.com/jour/article/downloadSuppFile/2841/782; Кириченко Ю.Ю., Ильгисонис И.С., Иванова Т.В. и др. Кардиоваскулотоксические проявления противоопухолевой терапии: влияние на ремоделирование миокарда и сосудистого русла. Кардиоваскулярная Терапия и Профилактика. 2021;20(7):2923. DOI:10.15829/1728- 8800-2021-2923.; Lyon AR, Lopez-Fernandez T, Couch SM, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;23(10):e333-e465. DOI:10.1093/eurheartj/ehac244.; Osterlund P, Kinos S, Pfeiffer P, et.al. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open. 2022;7(3):100427. DOI:10.1016/j.esmoop.2022.100427.; Peng J, Dong C, Wang C, et.al. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. Cancer Commun. 2018;38(1):22. DOI:10.1186/s40880-018-0292-1.; Visvikis A, Kyvelou SM, Pietri P, et.al. Cardiotoxic Profile and Arterial Stiffness of Adjuvant Chemotherapy for Colorectal Cancer. Cancer Manag Res. 2020;12:1175-85. DOI:10.2147/CMAR.S223032.; Campia U, Moslehi JJ, Amiri-Kordestani R, et al. Cardio-Oncology: Vascular and Metabolic Perspectives. Circulation. 2019;139(13):e579-e602. DOI:10.1161/CIR.0000000000000641.; Филатова А.Ю., Виценя М.В., Потехина А.В., и др. Атеросклероз брахиоцефальных артерий и артериальная жесткость у больных раком молочной железы. Кардиология. 2019;59(1S):43-52.; Shah CP, Mareb JS. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Ther Adv Cardiovasc Dis. 2019;13:1753944719843435. DOI:10.1177/1753944719843435.; Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12(6):409-25. DOI:10.1016/j.jash.2018.03.008.; Li M, Kroetz DL. Bevacizumab-Induced Hypertension: Clinical Presentation and Molecular Understanding. Pharmacol Ther. 2018;182:152-60. DOI:10.1016/j.pharmthera.2017.08.012.; Cohen JB, Geara AS, Hogan JJ, et al. Hypertension in Cancer Patients and Survivors Epidemiology, Diagnosis, and Management. JACC Cardio Oncol. 2019;1(2):238-51. DOI:10.1016/j.jaccao.2019. 11.009.; Catino AB, Hubbard RA, Chirinos JA, et al. Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma. Circ Heart Fail. 2018;11(3):e 004408. DOI:10.1161/CIRCHEARTFAILURE.117.004408.; Bottinor WJ, Shuey MM, Manouchehri A, et al. Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition. JACC Cardi Oncol. 2019;1(1):14-23. DOI:10.1016/j.jaccao.2019.07.002.; Res E, Kyvelou SM, Vlachopoulos C, et al. Metastatic malignancies and the effect on arterial stiffness and blood pressure levels: the possible role of chemotherapy. Onco Targets Ther. 2018:11:6785-93. DOI:10.2147/OTT.S156318.; Макеева Л.М., Емелина Е.И., Быкова А.В. и др. Сравнительный анализ нарушений сердечно-сосудистой системы у пациентов с хроническим миелолейкозом на фоне лечения ингибиторами тирозинкиназы. Клиническая Онкогематология. 2020;13(1):104-11. DOI:10.21320/2500-2139-2020-13-1-104-111.; Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017;31(11):2388-97. DOI:10.1038/leu.2017.245.; Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;225:33-53. DOI:10.1016/j.trsl.2020.06.012.; Плохова Е. В., Дундуа Д. П. Проблема тромбоза у пациентов со злокачественными заболеваниями. Кардиология. 2018;58(S9):19-28. DOI:10.18087/cardio.2523.; Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology. 2017;70(20):2552-65. DOI:10.1016/j.jacc.2017. 09.1095.; Matsumura C, Chisaki Y, Sakimoto S, et al. Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database. J Oncol Pharm Pract. 2018;24(1):22-7. DOI:10.1177/1078155216679025.; Васюк Ю.А., Гендлин Г.Е., Емелина Е.И. и др. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский Кардиологический Журнал 2021;26(9): 4703. DOI:10.15829/1560-4071-2021-4703.; Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70(8):926-38. DOI:10.1016/j.jacc.2017.06.047.; Lee I, Adimadhyam S, Nutescu EA, et al. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study. Pharmacotherapy. 2019;39(9):921-8. DOI:10.1002/phar.2310.; https://www.rpcardio.com/jour/article/view/2841
-
4Academic Journal
Authors: Melnik, A.A.
Source: Sovremennaya pediatriya; № 7(95) (2018): Sovremennaya pediatriya; 39-46
Современная педиатрия; № 7(95) (2018): Современная педиатрия; 39-46
Сучасна педіатрія; № 7(95) (2018): Сучасна педіатрія; 39-46Subject Terms: thrombophilia, children, venous thromboembolism, risk factors, laboratory methods, тромбофилия, дети, венозный тромбоэмболизм, фактор риска, лабораторные методы исследования, тромбофілія, діти, венозний тромбоемболізм, фактор ризику, лабораторні методи дослідження, 3. Good health
File Description: application/pdf
-
5Academic Journal
Source: Наука и здравоохранение.
Subject Terms: профилактика венозного тромбоэмболизма, treatment of venous thromboembolism, venous thromboembolism, лечение венозного тромбоэмболизма, исходы при венозном тромбоэмболизме, prevention of venous thromboembolism, венозный тромбоэмболизм в травматологии, venous thromboembolism in surgeon, venous thromboembolism in traumatology, outcomes of venous thromboembolism, венозный тромбоэмболизм, 3. Good health, венозный тромбоэмболизм в хирургии
-
6Academic Journal
Authors: B. S. Sukovatykh, L. N. Belikov, O. F. Savchuk, M. B. Sukovatykh
Source: Вестник хирургии имени И.И. Грекова, Vol 173, Iss 4, Pp 87-91 (2018)
Subject Terms: прадакса (дабигатран), варфарин, венозный тромбоэмболизм, pradaxa (dabigatran), warfarin, venous thromboembolism, Surgery, RD1-811
File Description: electronic resource
-
7Academic Journal
Authors: Usenko, O Yu, Smorzhevskyi, V Yi, Voyitiv, Yu Ya, Siyao, Yan
Source: Clinical anatomy and operative surgery; Том 16, № 1 (2017); 51-54
Клиническая анатомия и оперативная хирургия; Том 16, № 1 (2017); 51-54
Клінічна анатомія та оперативна хірургія; Том 16, № 1 (2017); 51-54Subject Terms: венозный тромбоэмболизм, перемежающаяся пневмокопрессия, венозний тромбоемболізм, переміжна пневмокопресія, venous thromboembolism, intermittent pneumo-compression, 3. Good health
File Description: application/pdf
-
8Academic Journal
Authors: N. S. Stuleva, D. A. Doronicheva, I. V. Khamani, E. A. Orudzhova, Н. С. Стулева, Д. А. Дороничева, И. В. Хамани, Э. В. Оруджова
Source: Obstetrics, Gynecology and Reproduction; Vol 14, No 4 (2020); 534-538 ; Акушерство, Гинекология и Репродукция; Vol 14, No 4 (2020); 534-538 ; 2500-3194 ; 2313-7347
Subject Terms: гипергомоцистеинемия, combined oral contraceptive, thrombotic complications, anticoagulant therapy, hemostasis disorders, venous thromboembolism, pregnancy, thrombophilia, antiphospholipid syndrome, hyperhomocysteinemia, комбинированные оральные контрацептивы, тромботические осложнения, антикоагулянтная терапия, нарушения гемостаза, венозный тромбоэмболизм, беременность, антифосфолипидный синдром
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/801/841; Liatsikos S. A., Tsikouras P., Manav B. et al. Inherited thrombophilia and reproductive disorders. J Turk Ger Gynecol Assoc. 2016;17(1):45–50. https://doi.org/10.5152/jtgga.2016.15212.; Макацария Н. А., Хизроева Д. Х., Бицадзе В. О. и др. Антифосфолипидные антитела у пациенток с неудачами ЭКО. Акушерство, Гинекология и Репродукция. 2014;8(4):93.; Беременность высокого риска. Под ред. А. Д. Макацария, Ф. А. Червенак, В. О. Бицадзе. М.: МИА, 2015. 920 с.; Акиньшина С. В., Макацария Н. А., Бицадзе В. О. и др. Тромбофилия и тромбоэмболические осложнения, связанные с использованием вспомогательных репродуктивных технологий. Акушерство, Гинекология и Репродукция. 2014;8(2):89–96.; Хизроева Д. Х., Михайлиди И., Стулёва Н. С. Значение определения протеина С в акушерской практике. Практическая медицина. 2013;(7):52–7.; Стулёва Н. С., Хизроева Д. Х., Машкова Т. Я., Абрамян Г. Р. Циркуляция антифосфолипидных антител и неудачи ЭКО. Акушерство, Гинекология и Репродукция. 2015;9(3):6–10. https://doi.org/10.17749/2070-4968.2015.9.3.006-010.; Peters K., Gordon N., Ricciotti N. et al. Hemostatic effects of two desogestrel-containing combined oral contraceptive regimens: a multinational, multicenter, randomized, open-label study. Clin Exp Obstet Gynecol. 2016;43(3):334–40.; Akinshina S., Makatsariya A., Bitsadze V. et al. Thromboprophylaxis in pregnant women with thrombophilia and a history of thrombosis. J Perinat Med. 2018;46(8):893–9. https://doi.org/10.1515/jpm-2017-0329.; Grandone E., Di Micco P. P., Villani М. et al. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.; Qublan H. S., Eid S. S., Ababneh H. A. et al. Acquired and inherited thrombophilia: implication in reccurent IVF and embryo transfer failure. Hum Reprod. 2006;21(10):2694–8. https://doi.org/10.1093/humrep/del203.; https://www.gynecology.su/jour/article/view/801
-
9Academic Journal
Authors: O. L. Barbarash, V. N. Karetnikova, V. V. Kashtalap, T. N. Zvereva, A. M. Kochergina, N. A. Kochergin, О. Л. Барбараш, В. Н. Каретникова, В. В. Кашталап, Т. Н. Зверева, А. М. Кочергина, Н. А. Кочергин
Source: Complex Issues of Cardiovascular Diseases; Том 9, № 2 (2020); 29-37 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 9, № 2 (2020); 29-37 ; 2587-9537 ; 2306-1278
Subject Terms: Венозный тромбоэмболизм, Antithrombotic therapy, Atherosclerosis, Thrombosis, Revascularization, Heart failure, Atrial fibrillation, Venous thromboembolism, Антитромботическая терапия, Атеросклероз Тромбоз, Реваскуляризация, Сердечная недостаточность, Фибрилляция предсердий
File Description: application/pdf
Relation: https://www.nii-kpssz.com/jour/article/view/712/495; https://www.nii-kpssz.com/jour/article/downloadSuppFile/712/422
-
10Academic Journal
Authors: N. K. Vereina, T. V. Movchan, V. S. Chulkov, Н. К. Вереина, Т. В. Мовчан, В. С. Чулков
Source: Aterotromboz = Atherothrombosis; № 1 (2020); 18-32 ; Атеротромбоз; № 1 (2020); 18-32 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2017-3
Subject Terms: молодой возраст, arterial thrombosis, venous thromboembolism, women, young age, артериальные тромбозы, венозный тромбоэмболизм, женщины
File Description: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/211/237; Бойцов С.А., Чучалин А.Г. (ред.). Диспансерное наблюдение больных хроническими неинфекционными заболеваниями и пациентов с высоким риском их развития. М.; 2014. 112 с. Режим доступа: https://minzdrav.midural.ru/upbads/document/1896/dispansernoe-nabIyude-nie-bolnyh-hniz-sa-chuchalin.pdf.; Воевода М.И., Ковалькова Н.А., Рагино Ю.А., Травникова Н.Ю., Денисова Д.В. Распространенность метаболического синдрома у жителей Новосибирска в возрасте от 25 до 45 лет. Терапевтический архив. 2016;88(10):51-56. doi:10.17116/terarkh2016881051; Eichinger S., Evers J.L.H., GLasier A., La Vecchia C., MartineLLi I., Skouby S. et aL. Venous thromboembolism in women: a specific reproductive health risk. Human Reproduction Update. 2013;19(5):471-482. doi:10.1093/humupd/dmt028.; Heinemann L.A., Dinger J.C. Range of published estimates of venous thromboembolism incidence in young women. Contraception. 2007;75(5):328-336. doi:10.1016/j.contraception.2006.12.018.; PutaaLa J. Ischemic stroke in the young: Current perspectives on incidence, risk factors, and cardiovascuLar prognosis. European Stroke Journal. 2016;1(1):28-40. doi:10.1177/2396987316629860.; PutaaLa J., Antti J., Metso A.J., Metso T.M., Konkola N., Kraemer Y et aL. Analysis of 1008 Consecutive Patients Aged 15 to 49 With First-Ever Ischemic Stroke. The Helsinki Young Stroke Registry. Stroke. 2009;40(4):1195-1203. doi:10.1161/STROKEAHA.108.529883.; WeiLL A., DaLichampt M., Raguideau F., Ricordeau Ph., BLotire P.-O., Rudant J. et aL. Low dose oestrogen combined oraL contraception and risk of puLmonary emboLism, stroke, and myocardiaL infarction in five miLLion French women: cohort study. BMJ. 2016;353. doi:10.1136/bmj.i2002.; Izadnegahdar M., Singer J., Lee M.K., Gao M., Thompson C.R., Kopec J., Humphries K.H. Do younger women fare worse? Sex differences in acute myocardiaL infarction hospitaLization and earLy mortaLity rates over ten years. J Women’s HeaLth. 2014;23(1):10-17. doi:10.1089/jwh.2013.4507.; Chandrasekhar J., GiLL A., Mehran R. Acute myocardiaL infarction in young women: current perspectives. Int J Womens Health. 2018;10:267-284. doi:10.2147/IJWH.S107371.; Lacruz B., Tiberio G., Latorre A., ViLLaLba J.C., BikdeLi B., Hirmerova J. et aL. RIETE Investigators Venous thromboemboLism in young aduLts: Findings from the RIETE registry. Eur J Intern Med. 2019;63:27-33. doi:10.1016/j.ejim.2019.02.007.; WendeLboe A.M., Raskob G.E. GLobaL burden of thrombosis: epidemioLogic aspects. Circulation Research. 2016;118(9):1340-1347. doi:10.1161/CIRCRESAHA.115.306841.; Prandoni P., Lensing A.W., Cogo A., Cuppini S., ViLLaLta S., Carta M. et aL. TheLong-term cLinicaL course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7. doi:10.7326/0003-4819-125-1-199607010-00001.; Prandoni P. Venous and arteriaL thrombosis: Two aspects of the same disease? Clinical Epidemiology. 2009;2009(1):1-6. doi:10.2147/cLep.s4780.; PrevitaLi E., BucciareLLi P., Passamonti S.M., MartineLLi I. Risk factors for venous and arteriaL thrombosis. Blood Transfus. 2011;9(2):120-138. doi:10.2450/2010.0066-10.; Prandoni P. Venous and arteriaL thrombosis: is there aLink? In: IsLam M. (ed.) Thrombosis and Embolism: From Research to Clinical Practice. 2016, pp. 273-283. doi:10.1007/5584_2016_121.; Prandoni P. Is there aLink between venous and arteriaL thrombosis? A reappraisaL. Int Emerg Med. 2020;15(1):33-36. doi:10.1007/s11739-019-02238-6.; Lind C., FLinterman L.E., Enga K.F., Severinsen M.T., Kristensen S.R., Braekkan S.K., Mathiesen E.B. Impact of incident venous thromboemboLism on risk of arteriaL thrombotic diseases. Circulation. 2014;129(8):855-863. doi:10.1161/CIRCULATIONAHA.113.004168.; Maino A., ALgra A., Peyvandi F., RosedaaL F.R., Siegerink B. HypercoaguLabiLity and the risk of recurrence in young women with myocardiaL infarction or ischaemic stroke: a cohort study. BMC Cardiovasc Disord. 2019;19:55. doi:10.1186/s12872-019-1040-4.; Андрияшкин А.В., Андрияшкин В.В., Арутюнов Г.П., Баринов В.Е., Бицадзе В.О., Бодыхов М.К. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015;9(4-2):1-52. Режим доступа: https://docpLayer.ru/65249323-Rossiyskie-kLin-icheskie-rekomendacii-po-diagnostike-Lecheniyu-i-profiLaktike-venoznyh-tromboemboLicheskih-osLozh-neniy-vteo.htmL.; Myakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R. et aL. International consensus statement on an update of the cLassification criteria for definite antiphosphoLipid syndrome. J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x.; RosendaaL F.R. Venous thromboemboLism: the roLe of genes, environment, and behavior. Hematology. Am Soc Hematol. Education Program. 2005;1:1-12. doi:10.1182/asheducation-2005.1.1.; Kearon C., Ageno W., Cannegieter S.C., Cosmi B., Geersing G.J., KyrLe P.A. Categorization of patients as having provoked or unprovoked venous thromboemboLism: guidance from the SSC of ISTH. J Thrombosis and Haemostasis. 2016;14(7):1480-1483. doi:10.1111/jth.13336.; MiLLett E.R.C., Peters S.A.E., Woodward M. Sex differences in risk factors for myocardiaL infarction: cohort study of UK Biobank participants. BMJ. 2018;363:k4247. doi:10.1136/bmj.k4247.; World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: WHO; 2015. 267 p Available at: https://www.who.int/reproductivehe-aIth/pubIications/famiIy_pIanning/MEC-5/en/; Dragoman M.V., Tepper N.K., Fu R., Curtis K.M., Chou R., Gaffield M.E. A systematic review and metaanalysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018;141(3):287-294. doi:10.1002/ijgo.12455.; Lidegaard O., Lokkegaard E., Svendsen A.L., Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890. doi:10.1136/bmj.b2890.; Roach R.E., Helmerhorst F.M., Lijfering W.M., Stijnen T., Algra A., Dekkers O.M. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst. Rev. 2015;2015(8):CD011054. doi:10.1002/14651858.CD011054.pub2.; Lidegaard O., Lokkegaard E., Jensen A., Skovlund C.W., Keiding N. Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception. N Engl J Med. 2012;366:2257-2266. doi:10.1056/NEJMoa1111840.; Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.-A., Harjola V.-P. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405.; Bhat V.M., Cole J.W., Sorkin J.D., Wozniak M.A., Malarcher A.M., Giles W.H. et al. Dose-response relationship between cigarette smoking and risk of ischemic stroke in young women. Stroke. 2008;39(9):2439-2443. doi:10.1161/STROKEAHA.107.510073.; Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. Jama. 2007;297(6):611-619. doi:10.1001/jama.297.6.611.; Deguchi H., Pecheniuk N.M., Elias D.J., Averell P.M., Griffin J.H. High-densitylipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112:893 -899. doi:10.1161/CIRCULATIONAHA.104.521344.; Ray J. Dyslipidemia, statins and venous thrombo-embolism: a potential risk factor and a potential treatment. Curr Opin Pulm Med. 2003;9(5):378-384. doi:10.1097/00063198-200309000-00007.; Ruckerl R., Ibald-Mulli A., Koenig W., Woelke G., Cyrys J., Heinrich J. et al. Air pollution and markers of inflammation and coagulation in patients with coronary heart disease. Am J Respir Crit Care Med. 2006;173(4):432-441. doi:10.1164/rccm.200507-1123OC.; Baccarelli A., Martinelli I., Zanobetti A., Grillo P., Hou L.F., Bertazzi P.A. et al. Exposure to particu-late air pollution and risk of deep vein thrombosis. Arch Int Med. 2008;168(9):920-927. doi:10.1001/archinte.168.9.920.; https://www.aterotromboz.ru/jour/article/view/211
-
11Academic Journal
Authors: F. A. Cheldieva, T. M. Reshetnyak, Ф. А. Чельдиева, Т. М. Решетняк
Source: Modern Rheumatology Journal; Том 13, № 3 (2019); 87-94 ; Современная ревматология; Том 13, № 3 (2019); 87-94 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2019-3
Subject Terms: цитокины, rheumatoid arthritis, inflammation, blood coagulation factors, thrombosis, venous thromboembolism, complement, cytokines, ревматоидный артрит, воспаление, факторы свертывания крови, тромбоз, венозный тромбоэмболизм, комплемент
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/937/902; Sira J, Eyre L. Physiology of haemostasis. Anaesthesia & Intensive Care Medicine. 2016; 17(2):79—82. doi:10.1016/j.mpaic.2015.11.004.; Hoffman M, Monroe DM. 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001 Jun;85(6):958-65.; Решетняк ВИ, Журавель СВ, Кузнецова НК, Писарев ВМ, Клычникова ЕВ, Сюткин ВЕ, Решетняк ТМ. Система гемостаза в норме и при трансплантации печени (обзор). Общая реаниматология. 2018;(5):85-96.; Струкова СМ. Основы физиологии гемостаза. 2-е изд. Москва: Издательство МГУ; 2013.; Aksu K, Donmez A, Keser G. Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management. Curr Pharm Des. 2012;18(11): 1478-93.; Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004 Jun 8; 109(22):2698-704. doi:10.1161/01.CIR.0000131660.51520.9A.; Margetic S. Inflammation and haemosta¬sis. Biochem Med (Zagreb). 2012:22(1):49-62. doi:10.11613/BM.2012.006.; Aisina RB, Mukhametova LI, Ostryakova EV, et al. Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thromboses in patients with the antiphospholipid syndrome. Biomed Khim. 2014 Jan-Feb;60(1):72-93. doi:10.1134/S1990750813010010.; Katz OB, Brenner B, Horowitz NA. Thrombosis in vasculitic disorders — clinical manifestations, pathogenesis and management. Thromb Res. 2015 Sep;136(3):504-12. doi:10.1016/j.thromres.2015.07.016. Epub 2015 Jul 15.; Westerweel PE, Verhaar MC. Endothelial progenitor cell dysfunction in rheumatic disease. Nat Rev Rheumatol. 2009 Jun;5(6): 332-40. doi:10.1038/nrrheum.2009.81.; Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol. 2012 Jun 18;12:41. doi:10.1186/1471-2377-12-41.; Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011 Jan 10;9:1. doi:10.1186/1741-7015-9-1.; Van den Oever IA, Sattar N, Nurmohamed MT. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis. 2014 Jun;73(6),954-7. doi:10.1136/annrheumdis-2013-204767. Epub 2014 Jan 15.; Thachil J. Platelets in Inflammatory Disorders: A Pathophysiological and Clinical Perspective. Semin Thromb Hemost. 2015 Sep; 41(6):572-581. doi:10.1055/s-0035-1556589. Epub 2015 Aug 15.; Borensztajn KS, von der Thu sen JH, Spek CA. The role of coagulation in chronic inflammatory disorders: A jack of all trades. Curr Pharm Des. 2011;17(1):9-16. doi:10.2174/138161211795049813.; Pottinger BE, Read RC, Paleolog EM, et al. Von Willebrand factor is an acute phase reactant in man. Thromb Res. 1989 Feb; 53(4):387-394. doi:10.1016/0049-3848(89)90317-4.; Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014 Oct;73(10):1774-80. doi:10.1136/annrheumdis-2013-203380. Epub 2013 Aug 7.; Van Doornum S, McColl G, Jenkins A, et al. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum. 2003 Jan;48(1):72-80. doi:10.1002/art.10735.; Bacon PA, Raza K, Banks MJ, et al. The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int Rev Immunol. 2002 Jan-Feb;21:1-17. doi:10.1080/08830180210413.; Ha nsel S, La ssig G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis. 2003 Sep; 170(1):177-80. doi:10.1016/S0021-9150(03)00281-8.; Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie. 2010 Jan;30(1):5-9. doi:10.1055/s-0037-1617146.; Mukubo Y, Kawamata M. Perioperative hypercoagulability in patients with rheumatoid arthritis: Sonoclot study. JAnesth. 2004; 18(1):62-4. doi:10.1007/s00540-003-0206-4.; Peters MJ, Nurmohamed MT, van Eyk I, et al. Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann Rheum Dis. 2009 Jul;68(7):1232-3. doi:10.1136/ard.2008.097485.; Cunningham M, Marks N, Barnado A, et al. Are Microparticles the Missing Link between Thrombosis and Autoimmune Diseases? Involvement in Selected Rheumatologic Diseases. Semin Thromb Hemost 2014 Sep;40(6):675-81. doi:10.1055/s-0034-1387924. Epub 2014 Aug 31.; Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009 Mar;101(3):439-51. doi:10.1160/TH08-08-0521.; Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999 Apr;30(2):111-42. doi:10.1016/S1040-8428(98)00044-4.; Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood. 2009 Jan 29;113(5):1112-21. doi:10.1182/blood-2008-06-163832. Epub 2008 Sep 18.; Knijff-Dutmer EA, Koerts J, Nieuwland R, et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum. 2002 Jun;46(6):1498-503. doi:10.1002/art.10312.; Van Eijk IC, Tushuizen ME, Sturk A, et al. Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis. Ann Rheum Dis. 2010 Jul;69(7): 1378-82. doi:10.1136/ard.2009.118372. Epub 2009 Nov 16.; Chauhan AK, Kisucka J, Brill A, et al. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 2008 Sep 1; 205(9):2065-74. doi:10.1084/jem.20080130. Epub 2008 Aug 11.; Holers VM, Banda NK. Complement in the Initiation and Evolution of Rheumatoid Arthritis. Front Immunol. 2018 May 28;9:1057. doi:10.3389/fimmu.2018.01057. eCollection 2018.; Trouw LA, Pickering MC. Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017 Sep;13(9):538-547. doi:10.1038/nrrheum.2017.125. Epub 2017 Aug 10.; Wiegner R, Chakraborty S, Huber-Lang M. Complement-coagulation crosstalk on cellular and artificial surfaces. Immunobiology. 2016 Oct;221;(10):1073-9. doi:10.1016/j.imbio.2016.06.005. Epub 2016 Jun 19.; Foley JH. Examining coagulation-com-plement crosstalk: complement activation and thrombosis. Thromb Res. 2016 May;141 Suppl 2:S50-4. doi:10.1016/S0049-3848(16)30365-6.; Wiedmer T, Esmon CT, Sims PJ. On the Mechanism by Which Complement Proteins C5b-9 Increase Platelet Prothrombinase Activity. JBiol Chem. 1986 Nov 5;261(31): 14587-92.; Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006 Oct 1; 177(7):4794-802. doi:10.4049/jimmunol.177.7.4794.; Langer F, Spath B, Fischer C, et al. Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase. Blood. 2013 Mar 21;121(12):2324-35. doi:10.1182/blood-2012-10-460493. Epub 2013 Jan 11.; Egge KH, Thorgersen EB, Pischke SE, et al. Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. Immunobiology. 2015 August;220(8):999-1005. doi:10.1016/j.imbio.2015.04.002. Epub 2015 Apr 27.; Landsem A, Fure H, Christiansen D, et al. The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood. Clin Exp Immunol. 2015 Oct;182(1):81-9. doi:10.1111/cei.12663. Epub 2015 Aug 2.; Ovstebo R, Hellum M, Aass HC, et al. Microparticle-associated tissue factor activity is reduced by inhibition of the complement protein 5 in Neisseria meningitidis-exposed whole blood. Innate Immun. 2014 Jul;20(5): 552-60. doi:10.1177/1753425913502099. Epub 2013 Sep 19.; Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989 May 25;264(15):9053-60.; Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996 Mar; 7(2):157-61. doi:10.1097/00001721-199603000-00011.; Boos CJ, Lip GY. Assessment of mean platelet volume in coronary artery disease-what does it mean? Thromb Res. 2007;120(1): 11-13. doi:10.1016/j.thromres.2006.09.002. Epub 2006 Oct 12.; Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets. 2000 Feb;11(1):28-32. doi:10.1080/09537100075760.; Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009 Jan;101(1):151-6. doi:10.1160/TH08-03-0186.; Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, et al. Platelet function in rheumatoid arthritis: arthritic and cardiovas-cular implications. Rheumatology International. 2011 Feb;31(2):153-64. doi:10.1007/s00296-010-1446-x.; Muscari A, De Pascalis S, Cenni A, et al. Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost. 2008 Jun;99(6):1079-84. doi:10.1160/TH07-12-0712.; Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: Cause or consequence? Int Immunopharmacol. 2015 Sep;28(1):655-65. doi:10.1016/j.intimp.2015.07.044. Epub 2015 Aug 4.; Long AT, Kenne E, Jung R, et al. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost. 2016 Mar;14(3):427-37. doi:10.1111/jth.13235. Epub 2016 Feb 9.; Branchford BR, Carpenter SL. The Role of Inflammation in Venous Thromboembolism. FrontPediatr. 2018 May 23;6:142. doi:10.3389/fped.2018.00142. eCollection 2018.; Bisoendial RJ, Levi M, Tak PP, Stroes ES. The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardio-vascular events. Semin Thromb Hemost. 2010 Jul;36(4):452-7. doi:10.1055/s-0030-1254054. Epub 2010 Jul 7.; Bacani AK, Gabriel SE, Crowson CS, et al. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum. 2012 Jan;64(1): 53-61. doi:10.1002/art.33322.; Matta F, Singala R, Yaekoub AY, et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost. 2009 Jan; 101(1):134-8. doi:10.1160/TH08-08-0551.; Kang JH, Keller JJ, Lin YK, Lin HC. A population-based case-control study on the association between rheumatoid arthritis and deep vein thrombosis. J Vasc Surg. 2012 Dec; 56(6):1642-8. doi:10.1016/j.jvs.2012.05.087. Epub 2012 Oct 22.; Page C, Pitchford S. Platelets and allergic inflammation. Clin Exp Allergy. 2014 Jul;44(7): 901-913. doi:10.1111/cea.12322.; Edwards CJ, Arden NK, Fisher D, et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford). 2005 Nov;44(11):1394-8. doi:10.1093/rheumatology/kei024. Epub 2005 Jul 19.; Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010 Feb;49(2):295-307. doi:10.1093/rheumatology/kep366. Epub 2009 Nov 27.; Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and metaanalysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011 Nov 1;108(9):1362-70. doi:10.1016/j.amj-card.2011.06.054. Epub 2011 Aug 17.; Macias I, Garcia-Perez S, Ruiz-Tudela M, et al. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol. 2005 Nov;32(11):2102-8.; Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of car-diovascular disease. Circulation. 2001 Apr 3; 103(13):1813-8. doi:10.1161/01.CIR.103.13.1813.; Zoller B, Li X, Sundquist J, et al. Risk of venous thromboembolism in first- and second-generation immigrants in Sweden. Eur J Intern Med. 2012 Jan;23(1):40-7. doi:10.1016/j.ejim.2011.07.015. Epub 2011 Aug 23.; Kim SC, Solomon DH, Liu J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17. doi:10.1016/j.amjmed.2014.11.025. Epub 2014 Dec 20.; Сатыбалдыева МА. Ревматоидный артрит и венозные тромбоэмболические осложнения. Научно-практическая ревматология. 2016;54(4):456-62. doi:10.14412/1995-4484-2016-456-462.
-
12Academic Journal
Authors: N. I. Sglushkov, M. A. Ivanov, M. S. Khvostova, A. A. Mishchenko, P. B. Bondarenko, S. A. Vinnychuk, ZH. M. Pikhanova
Source: Кубанский научный медицинский вестник, Iss 5, Pp 25-29 (2016)
Subject Terms: венозный тромбоэмболизм, метаболический синдром, артериальный тромбоз, атеросклероз, venous thromboembolism, metabolic syndrome, arterial thrombosis, atherosclerosis, Medicine
File Description: electronic resource
-
13Academic Journal
Subject Terms: венозний тромбоемболізм, передопераційна профілактика, абдомінальна хірургія, гепарин, еноксапарин, кава-фільтр, рівароксабан, венозный тромбоэмболизм, предоперационная профилактика, абдоминальная хирургия, эноксапарин, кава-фильтр, ривароксабан, venous thromboembolism, preoperative prophylaxis, abdominal surgery, heparin, enoxaparin, cavafilter, rivaroxaban, 616.14-005.6/.7-089
File Description: application/pdf
Relation: Сяо Ян Эффективность предоперационной профилактики венозного тромбоэмболизма в абдоминальной хирургии / Ян Сяо // Вісник проблем біології і медицини. – 2018. – Вип. 1, т. 2 (143). – С. 205–211.; https://repository.pdmu.edu.ua/handle/123456789/15749
-
14Academic Journal
Authors: A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev
Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 6, Pp 634-639 (2015)
Subject Terms: тромбоз, венозный тромбоэмболизм, злокачественные новообразования, онкология, новые оральные антикоагулянты, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701
File Description: electronic resource
-
15Academic Journal
Authors: A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev
Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 6, Pp 634-639 (2015)
Subject Terms: злокачественные новообразования, онкология, venous thromboembolism, новые оральные антикоагулянты, new oral anticoagulants, RM1-950, 3. Good health, 03 medical and health sciences, тромбоз, 0302 clinical medicine, RC666-701, oncology, cancer, Diseases of the circulatory (Cardiovascular) system, Therapeutics. Pharmacology, венозный тромбоэмболизм, thrombosis
Access URL: https://www.rpcardio.com/jour/article/download/300/315
https://doaj.org/article/09e3b2e419a44444b82a76ce2c5eba90
https://doaj.org/article/70e0d63e0b394ec19770bb724b684e1a
https://www.rpcardio.com/jour/article/download/300/315
https://www.rpcardio.com/jour/article/view/300
https://core.ac.uk/display/87816523 -
16Academic Journal
Authors: C. И. Капустин
Source: Тромбоз, гемостаз и реология.
Subject Terms: hereditary thrombophilia, venous thromboembolism, тест генерации тромбина, наследственная тромбофилия, thrombin generation test, венозный тромбоэмболизм, 3. Good health
-
17Academic Journal
Authors: A. V. Demyanenko, S. I. Kapustin, V. V. Soroka, P. V. Chechulov, А. В. Демьяненко, С. И. Капустин, В. В. Сорока, П. В. Чечулов
Source: Medical Genetics; Том 14, № 12 (2015); 33-38 ; Медицинская генетика; Том 14, № 12 (2015); 33-38 ; 2073-7998
Subject Terms: risk factor, тромбоэмболия легочной артерии, венозный тромбоэмболизм, наследственная тромбофилия, ген, фактор риска, deep vein thrombosis, pulmonary embolism, venous thromboembolism, inherited thrombophilia, gene
File Description: application/pdf
Relation: https://www.medgen-journal.ru/jour/article/view/77/25; Wong P., Baglin T. Epidemiology, risk factors and sequelae of venous thromboembolism // Phlebology. - 2012. - Vol. 27 (Suppl. 2). - P. 2-11.; Dahlbаck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders // Blood. - 2008. - Vol. 112(1). - P. 19-27.; Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothormbin (20210G>A) mutations in adults with a history of idiopathic VTE and their adult family members // Genet. Med. - 2011. - Vol. 13. - P. 67-76.; Baglin T., Gray E., Greaves M. et al. British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia // Br. J. Haematol. - 2010. - Vol. 149. - P. 209-220.; Heit J.A. Thrombophilia: common questions on laboratory assessment and management // Hematology Am. Soc. Hematol. Educ. - 2007. - Vol. 1. - P. 127-135.; Gohil R., Peck G., Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls // ThrombHaemost. - 2009. - Vol. 102(2). - P. 360-370.; Rosendaal F.R., Reitsma P.H. Genetics of venous thrombosis // Journal of Thrombosis and Haemostasis. - 2009. - Vol. 7 (Suppl. 1). - P. 301-304.; Simone B., De Stefano V., Leoncini E., Zacho J. et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolatereductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls // Eur. J. Epidemiol. - 2013. - Vol. 28(8). - P. 621-647.; Rasmussen-Torvik L.J., Cushman M., Tsai M.Y., Zhang Y. et al. The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study // Thromb. Res. - 2007. - Vol. 121(1). - P. 1-7.; Chen X.D., Tian L., Li M., Jin W. et al. Relationship between endothelial cell protein C receptor gene 6936A/G polymorphisms and deep venous thrombosis // Chin. Med. J. (Engl.). - 2011. - Vol. 124(1). - P. 72-75.; vanHylckamaVlieg A., Komanasin N., Ariens R.A. et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis // Br. J. Haematol. - 2002. - Vol. 119(1). - P. 169-175.
-
18Academic Journal
Authors: Клiгуненко, О. М.
Source: Pain, Anaesthesia and Intensive Care; № 2(79) (2017); 62-69
PAIN, ANAESTHESIA & INTENSIVE CARE; № 2(79) (2017); 62-69
Біль, знеболення та інтенсивна терапія; № 2(79) (2017); 62-69Subject Terms: венозный тромбоэмболизм, тромбоэмболия лёгочной артерии, гипотензия, коморбидность, рак, лечение, антикоагулянты, искусственная вентиляция легких, venous thromboembolism, pulmonary embolism, hypotension, comorbidity, cancer, anticoagulant treatment, mechanical lung ventilation, венозний тромбоемболізм, тромбоемболія легеневої артерії, гіпотензія, коморбідність, лікування, антикоагулянти, штучна вентиляція легенів, 616.131/.14 005.6/.7/.8:616.8 009.16] 08:615.273:615.816, 3. Good health
File Description: application/pdf
Access URL: http://jpaic.aaukr.org/article/view/107450
-
19Academic Journal
Authors: ФЕДОРОВ А.И., КАЩЕНКО В.А., КЛИМОВ А.С., ЛЕБЕДЕВА Н.Н.
File Description: text/html
-
20Academic Journal
Authors: ПОЛЯКОВА АНАСТАСИЯ ПАВЛОВНА, ШМЕЛЕВА В.М., БЛИНОВ М.Н., СОЛДАТЕНКОВ В.Е., КАРГИН В.Д., ПАПАЯН Л.П., КАПУСТИН С.И.
Subject Terms: ВЕНОЗНЫЙ ТРОМБОЭМБОЛИЗМ, ПРОВОСПАЛИТЕЛЬНЫЕ ЦИТОКИНЫ, ГЕН, ПОЛИМОРФИЗМ
File Description: text/html
